{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:23:27Z","timestamp":1774765407155,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.trim.2019.04.002","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T16:38:25Z","timestamp":1557333505000},"page":"101207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol"],"prefix":"10.1016","volume":"56","author":[{"given":"Paolo","family":"Malvezzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Fischman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Rigault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Christine","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Raskovalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Janbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.trim.2019.04.002_bb0005","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kasiske","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2019.04.002_bb0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: a critical reappraisal","volume":"11","author":"Lamb","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0020","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2019.04.002_bb0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2019.04.002_bb0030","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2215\/CJN.03820609","article-title":"Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm","volume":"4","author":"Gaston","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2019.04.002_bb0035","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1097\/TP.0000000000001244","article-title":"Calcineurin inhibitor nephrotoxicity in the era of antibody-mediated rejection","volume":"100","author":"Naesens","year":"2016","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2019.04.002_bb0040","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2019.04.002_bb0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0055","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in Belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.trim.2019.04.002_bb0065","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.05840710","article-title":"Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study","volume":"6","author":"Rostaing","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2019.04.002_bb0070","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1097\/TP.0000000000001755","article-title":"A randomized controlled clinical trial comparing Belatacept with tacrolimus after De novo kidney transplantation","volume":"101","author":"de Graav","year":"2017","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2019.04.002_bb0075","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/TP.0000000000002192","article-title":"Conversion to belatacept in maintenance kidney-transplant patients: a retrospective multicenter European study","volume":"102","author":"Darres","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2019.04.002_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1568008053174723","article-title":"CXCR3-binding chemokines: novel multifunctional therapeutic targets","volume":"5","author":"Lazzeri","year":"2005","journal-title":"Curr. Drug Targets Immune Endocr. Metabol. Disord."},{"key":"10.1016\/j.trim.2019.04.002_bb0085","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-6143.2004.00354.x","article-title":"Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction","volume":"4","author":"Hu","year":"2004","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0090","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1681\/ASN.2004100836","article-title":"Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG)","volume":"16","author":"Hauser","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2019.04.002_bb0095","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1600-6143.2009.02645.x","article-title":"Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis","volume":"9","author":"Schaub","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0100","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/j.1600-6143.2011.03680.x","article-title":"Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection","volume":"11","author":"Jackson","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0105","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/ajt.12426","article-title":"Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury","volume":"13","author":"Hricik","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0110","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1681\/ASN.2014121234","article-title":"Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients","volume":"26","author":"Hricik","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2019.04.002_bb0115","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ekir.2017.06.010","article-title":"Rapid biolayer interferometry measurements of urinary CXCL9 to detect cellular infiltrates noninvasively after kidney transplantation","volume":"2","author":"Gandolfini","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.trim.2019.04.002_bb0120","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/ajt.13863","article-title":"Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis","volume":"16","author":"Z1","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.trim.2019.04.002_bb0130","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.mad.2005.11.001","article-title":"Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment","volume":"127","author":"Saule","year":"2006","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.trim.2019.04.002_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156200","article-title":"Remodeling of B-cell subsets in blood during Pegylated IFN\u03b1-2a therapy in patients with chronic hepatitis B infection","volume":"11","author":"Aspord","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.trim.2019.04.002_bb0140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40620-017-0411-0","article-title":"Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism","volume":"30","author":"Schulte","year":"2017","journal-title":"J. Nephrol."},{"key":"10.1016\/j.trim.2019.04.002_bb0145","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","article-title":"Safety and efficacy outcomes 3 years after switching to Belatacept from a Calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial","volume":"69","author":"Griny\u00f3","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.trim.2019.04.002_bb0150","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies","volume":"18","author":"Bray","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0155","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/ajt.14939","article-title":"Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: an analysis of the BENEFIT and BENEFIT-EXT trial cohorts","volume":"18","author":"Everly","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0160","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/TP.0000000000000717","article-title":"Differential effects of calcineurin and mammalian target of rapamycin inhibitors on alloreactive Th1, Th17, and regulatory T cells","volume":"99","author":"Gallon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2019.04.002_bb0165","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0952-7915(02)00378-3","article-title":"Mechanisms of transplant tolerance induction using costimulatory blockade","volume":"14","author":"Wekerle","year":"2002","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.trim.2019.04.002_bb0170","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/j.1600-6143.2011.03680.x","article-title":"Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection","volume":"11","author":"Jackson","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ajt.12526","article-title":"Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection","volume":"14","author":"Kim","year":"2014","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/imm.12947","article-title":"End-stage renal disease, dialysis kidney transplantation and their impact CD4+ T-cell differentiation","volume":"155","author":"Schaier","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.trim.2019.04.002_bb0185","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/ajt.14013","article-title":"Prospective analyses of circulating B cell subsets in ABO-compatible and ABO-incompatible kidney transplant recipients","volume":"17","author":"Schl\u00f6\u00dfer","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.04.002_bb0190","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/tri.12605","article-title":"Does belatacept improve outcomes for kidney transplant recipients? A systematic review","volume":"28","author":"Talawila","year":"2015","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2019.04.002_bb0195","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2146\/ajhp120770","article-title":"Risk of posttransplant lymphoproliferative disorder associated with use of belatacept","volume":"70","author":"Martin","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.trim.2019.04.002_bb0200","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/TP.0b013e3181efcffd","article-title":"Determinants of long-term graft outcome in transplant glomerulopathy","volume":"90","author":"John","year":"2010","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2019.04.002_bb0205","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1097\/01.ASN.0000020390.29418.70","article-title":"Repuncturing the renal biopsy: strategies for molecular diagnosis in nephrology","volume":"13","author":"Kretzler","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2019.04.002_bb0210","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1046\/j.1523-1755.2001.00030.x","article-title":"Convergence of European Renal Transplant Pathology Assessment Procedures (CERTPAP) Project. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP project","volume":"60","author":"Furness","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2019.04.002_bb0215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2215\/CJN.00390705","article-title":"Protocol transplant biopsies: an underutilized tool in kidney transplantation","volume":"1","author":"Rush","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2019.04.002_bb0220","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ekir.2017.06.010","article-title":"Rapid biolayer interferometry measurements of urinary CXCL9 to detect cellular infiltrates noninvasively after kidney transplantation","volume":"2","author":"Gandolfini","year":"2017","journal-title":"Kidney Int. Rep."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327419300231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327419300231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:58:52Z","timestamp":1760810332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327419300231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":44,"alternative-id":["S0966327419300231"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2019.04.002","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2019.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101207"}}